oral reversible selective BTK kinase inhibitor
related cmpds in dev. for inflamm. conditions
from rational design of prior crystallized leads
ACS Med. Chem. Lett., Sep. 22, 2020
Bristol Myers Squibb, Princeton, NJ
BMS-986143
BMS-986143 is a potent, reversible inhibitor of the Bruton’s tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible drugs for oncology. The safety bar is much…